Tenax Therapeutics (NASDAQ:TENX) Earns Buy Rating from Analysts at Guggenheim

Investment analysts at Guggenheim assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report issued on Monday, Briefing.com reports. The brokerage set a “buy” rating and a $16.00 price target on the specialty pharmaceutical company’s stock. Guggenheim’s target price indicates a potential upside of 374.78% from the stock’s previous close.

Several other equities analysts also recently commented on the company. William Blair initiated coverage on Tenax Therapeutics in a research report on Monday, September 30th. They issued an “outperform” rating for the company. StockNews.com initiated coverage on shares of Tenax Therapeutics in a report on Thursday, September 26th. They issued a “sell” rating for the company.

Tenax Therapeutics Trading Down 2.3 %

Tenax Therapeutics stock opened at $3.37 on Monday. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $61.20. The business’s 50-day moving average price is $3.74 and its two-hundred day moving average price is $3.57.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, beating the consensus estimate of ($1.99) by $0.16. As a group, equities research analysts forecast that Tenax Therapeutics will post -6.75 EPS for the current year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.